Calò, P.; Pianton, N.; Basle, A.; Vasiljevic, A.; Barritault, M.; Beuriat, P.A.; Faure-Conter, C.; Leblond, P.
Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma. Cancers 2023, 15, 1036.
https://doi.org/10.3390/cancers15041036
AMA Style
Calò P, Pianton N, Basle A, Vasiljevic A, Barritault M, Beuriat PA, Faure-Conter C, Leblond P.
Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma. Cancers. 2023; 15(4):1036.
https://doi.org/10.3390/cancers15041036
Chicago/Turabian Style
Calò, Pierluigi, Nicolas Pianton, Alexandre Basle, Alexandre Vasiljevic, Marc Barritault, Pierre Aurélien Beuriat, Cécile Faure-Conter, and Pierre Leblond.
2023. "Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma" Cancers 15, no. 4: 1036.
https://doi.org/10.3390/cancers15041036
APA Style
Calò, P., Pianton, N., Basle, A., Vasiljevic, A., Barritault, M., Beuriat, P. A., Faure-Conter, C., & Leblond, P.
(2023). Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma. Cancers, 15(4), 1036.
https://doi.org/10.3390/cancers15041036